Yıl: 2013 Cilt: 2 Sayı: 1 Sayfa Aralığı: 46 - 49 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık

Öz:
Geçici myeloproliferatif hastalık (GMPH), Trizomi 21 (DownSendromu) tanısı ile izlenen infantların yaklaşık %10undaortaya çıkabilen, periferik kanda myeloid blastların artımı ilekarakterize bir durumdur. GMPH, Down Sendromunnunişaretlerini taşımayan mozaik trizomi 21 hastalarında dagörülebilir. GMPHlı infantlarda ilk 3 yılda akut m ega¬karyoblastik lösemi (AML -M7) gelişme riski yaklaşık %30dur. Biz burada GMPH gelişen Down Sendromlu bir vakasunduk. Down sendromlu yenidoğanlarda hepasopslenom egali, lökositoz veya trombositopeni ve periferik kan yaymaincelemeside myeloblast saptanması durumunda GMPHdüşünülmesinin önemine vurgu yapmak istedik .
Anahtar Kelime:

Konular: Cerrahi

Transient myeloproliferative disordes in A newborns with down syndrome

Öz:
Transient myeloproliferative disease (TMD), defined bycirculating nonlymphoid blast in the peripheral blood, occursin approximately 10% of infants with constitutional trisomy21 (Down syndrome). The TMD phenotype may also occur inn ewborns who do not have clinical signs of Down syndromebut nonconstitutional trisomy 21 due to mosaicism. Acutemega-karyoblastic leukemia (AML -M7) develops in approx ima¬tely 30 % of the cases with TMD within the first threeyears of life. In this case report, a newborn with TMD withDown syndrome is presented. We emphasize the importa nce of the peripheral blood smear examination in newbornswith DS, especially with hepatosplenomegaly, leukocytosisor throm¬bocytopenia and myeloblast of the peripheralsmear, in order to diagnose TMD.
Anahtar Kelime:

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
  • 1. Roy A, Roberts I, Vyas P. Biology and manag ement of transient abnormal myelopoiesis (TAM) in children with Down syndrome. Semin Fetal Neonatal Med. 2012;17:196 -201.
  • 2. Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, Pekrun A, Macakova -Reinhardt K, Reinhardt D. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008 ;111:2991 - 8.
  • 3. Massey GV, Zipursky A, Chang MN, Doyle JJ, N asim S, Taub JW, Ravindranath Y, Dahl G, Weinstein HJ; A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): children’s Oncology Group (COG) study POG -9481. Blood 2006;107: 4606 -13.
  • 4. GH Judih: Chromosomal Clinical Abnormalities, In: Richar E. Behrman, Robert M. Kliegman, Hall B. Jenson (Eds), Nelson Textbook of Pediatrics. 17th edition. Saunders an Imprint of Elsevier Science, USA, 2004: 382 -91.
  • 5. Bessler M, Mason JP,Link DC, Wilson DB: Inherited Bone Marrow Syndromes, In: Stuart H. Orkin, David G. Nathan, David Ginsburg, A. Th omas Look, David E. Fisher, Samuel E. Lux (Eds), Nathan and Oski’s Hematology of Infancy and Childhood. 7th edition. Saunders an Imprint of Elsevier Science, USA,2009: 307 -95.
  • 6. Lange B. The management of neoplastic diso rders of haematopoiesis in children with Down’s syndrome. Br J Haematol. 2000;110(3):512 - 524.
  • 7. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355:165 -69.
  • 8. Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, Loew TW, Arceci RJ, Ba rnard D, Doyle J, Massey G, Perentesis J, Ravin dranath Y, Taub J, Smith FO. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood 2011;118:6752 -9.
  • 9. Smrcek JM, Baschat AA, Germer U, Gloeckner- Hofmann K, Embruch U. Fetal hydrops and h epatosplenomegaly in the second half of pregnancy: a sign of myeloproliferative disorder in fetuses with trisomy 21. Ultrasound Obstet G ynecol 2001;17:403 -9.
  • 10. Groet J, McElwaine S, Spinelli M, Rinaldi A, Burtscher I, Mulligan C, Mensah A, Cavani S, Dagna-Bricarelli F, Basso G, Cotter FE, Nizetic D. Acquired mutations in GATA1 in neonates with Down’s syndrome with transient myeloid diso rder. Lancet 2003;361:1617 -20.
  • 11. Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, Amariglio N, Biondi A, Muler I, Rechavi G, Kempski H, Haas OA, Izraeli S. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003;102:981 -86.
  • 12. Xu G, Nagano M, Kanezaki R, Toki T, Hayashi Y, Taketani T, Taki T, Mitui T, Koike K, Kato K, Ima izumi M, Sekine I, Ikeda Y, Hanada R, Sako M, Kudo K, Kojima S, Ohneda O, Yamamoto M, Ito E. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 2003;102:2960 -68.
  • 13. Cabelof DC, Patel HV, Chen Q, van Remmen H, Matherly LH, Ge Y, Taub JW. Mutational spec trum at GATA1 provides insights into mutagen esis and leukemogenesis in Down syndrome. Blood 2009;114:2753 -63.
  • 14. Pine SR, Guo Q, Yin C, Jayabose S, Levendoglu - Tugal O, Ozkaynak MF, Sandoval C. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndro me. Leuk Res 2005;29: 1353-56.
  • 15. Alford KA, Reinhardt K, Garnett C, Norton A, Böhmer K, von Neuhoff C, Kolenova A, Marchi E, Klusmann JH, Roberts I, Hasle H, Reinhardt D, Vyas P; International Myeloid Leukemia -Down Syndrome Study Group. Analysis of GATA1 mutations in Down syndrome transient myeloprol iferative disorder and myeloid leukemia. Blood 2011;118:2222 -38.
APA DEMİRCİOĞLU F, ALTUNHAN H, Bekdas M, GÖKSÜGÜR S, YEŞİLLER E, SARAÇ E, KISMET E (2013). Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık. , 46 - 49.
Chicago DEMİRCİOĞLU Fatih,ALTUNHAN Hüseyin,Bekdas Mervan,GÖKSÜGÜR Sevil Bilir,YEŞİLLER Erkan,SARAÇ Esma Gökçen,KISMET Erol Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık. (2013): 46 - 49.
MLA DEMİRCİOĞLU Fatih,ALTUNHAN Hüseyin,Bekdas Mervan,GÖKSÜGÜR Sevil Bilir,YEŞİLLER Erkan,SARAÇ Esma Gökçen,KISMET Erol Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık. , 2013, ss.46 - 49.
AMA DEMİRCİOĞLU F,ALTUNHAN H,Bekdas M,GÖKSÜGÜR S,YEŞİLLER E,SARAÇ E,KISMET E Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık. . 2013; 46 - 49.
Vancouver DEMİRCİOĞLU F,ALTUNHAN H,Bekdas M,GÖKSÜGÜR S,YEŞİLLER E,SARAÇ E,KISMET E Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık. . 2013; 46 - 49.
IEEE DEMİRCİOĞLU F,ALTUNHAN H,Bekdas M,GÖKSÜGÜR S,YEŞİLLER E,SARAÇ E,KISMET E "Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık." , ss.46 - 49, 2013.
ISNAD DEMİRCİOĞLU, Fatih vd. "Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık". (2013), 46-49.
APA DEMİRCİOĞLU F, ALTUNHAN H, Bekdas M, GÖKSÜGÜR S, YEŞİLLER E, SARAÇ E, KISMET E (2013). Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık. Abant Tıp Dergisi, 2(1), 46 - 49.
Chicago DEMİRCİOĞLU Fatih,ALTUNHAN Hüseyin,Bekdas Mervan,GÖKSÜGÜR Sevil Bilir,YEŞİLLER Erkan,SARAÇ Esma Gökçen,KISMET Erol Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık. Abant Tıp Dergisi 2, no.1 (2013): 46 - 49.
MLA DEMİRCİOĞLU Fatih,ALTUNHAN Hüseyin,Bekdas Mervan,GÖKSÜGÜR Sevil Bilir,YEŞİLLER Erkan,SARAÇ Esma Gökçen,KISMET Erol Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık. Abant Tıp Dergisi, vol.2, no.1, 2013, ss.46 - 49.
AMA DEMİRCİOĞLU F,ALTUNHAN H,Bekdas M,GÖKSÜGÜR S,YEŞİLLER E,SARAÇ E,KISMET E Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık. Abant Tıp Dergisi. 2013; 2(1): 46 - 49.
Vancouver DEMİRCİOĞLU F,ALTUNHAN H,Bekdas M,GÖKSÜGÜR S,YEŞİLLER E,SARAÇ E,KISMET E Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık. Abant Tıp Dergisi. 2013; 2(1): 46 - 49.
IEEE DEMİRCİOĞLU F,ALTUNHAN H,Bekdas M,GÖKSÜGÜR S,YEŞİLLER E,SARAÇ E,KISMET E "Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık." Abant Tıp Dergisi, 2, ss.46 - 49, 2013.
ISNAD DEMİRCİOĞLU, Fatih vd. "Down sendromlu bir yenidoğanda geçici myeloproliferatif hastalık". Abant Tıp Dergisi 2/1 (2013), 46-49.